{
    "clinical_study": {
        "@rank": "119396", 
        "arm_group": [
            {
                "arm_group_label": "Marealis refined peptide concentrate", 
                "arm_group_type": "Experimental", 
                "description": "Participants are provided in double blinded fashion to Marealis refined peptide concentrate"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants are provided in double blinded fashion to Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypertension is an important risk factor of cardiovascular (CVD) and renal diseases.\n      Epidemiological studies show that there is a direct relationship between blood pressure and\n      CVD, and cardiovascular mortality increases progressively throughout the range of blood\n      pressure, including the prehypertensive range.  There is also evidence from cell and animal\n      studies that shrimp tissue hydrolysates may have higher ACE inhibitory activity than other\n      marine protein hydrolysates.  It is hypothesized that Marealis RPC (refined peptide\n      concentrate)will lower systolic blood pressure in subjects with elevated blood pressure."
        }, 
        "brief_title": "Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects", 
        "condition": "Prehypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Prehypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 30 to 75 years inclusive (independent and home-living subject).\n\n          -  If female, subject is not of child bearing potential.  Defined as females who have\n             had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal\n             (natural or surgically with > 1 year since last menstruation); OR Female subject of\n             childbearing potential must agree to use a medically approved method of birth control\n             and have a negative urine pregnancy test result.\n\n          -  Mild or moderate hypertension (SBP 140-160 mmHg and DBP \u2264 100mmHg) (mean of office\n             blood pressure measurements at the two first study visits during run-in period\n             (visits 1 (-4 week) and 2 (-2 week)).  Average office SBP baseline to be as close to\n             150mm Hg (i.e. 147-149 mmHg) as possible.\n\n          -  Body weight \u226560kg\n\n          -  Stable body weight (self-reported weight gain or loss <5kg in the past three months)\n\n          -  Has given voluntary, written, informed consent to participate in the study\n\n          -  Agrees to comply with study procedures including willingness to fast at least 12\n             hours before blood samples and abstain from alcohol two days prior to blood sampling\n             and blood pressure measurement and abstain from coffee at least 14 hours before blood\n             pressure measurement and abstain from physical exercise at least 4 hours before blood\n             pressure measurement\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the\n             course of the trial\n\n          -  Body mass index \u2265 35 kg/m2\n\n          -  Antihypertensive drug treatment, regular high dose NSAID treatment, use of\n             cyclosporine or tacrolimus\n\n          -  Any history of cardiovascular disease (myocardial infarction, unstable angina\n             pectoris, coronary artery bypass graft, percutaneous transluminal coronary\n             angioplasty, temporal ischemic attack) including stroke and congestive heart failure\n\n          -  Dementia, hypertensive retinopathy, left ventricular dysfunction or peripheral artery\n             disease\n\n          -  Anemia, abnormal electrolytes, proteinuria, abnormal liver, kidney and thyroid\n             function (except subjects on thyroid replacement therapy)\n\n          -  Clinically significant laboratory results\n\n          -  Any other clinically significant abnormality in hematology and/or biochemistry at the\n             Investigator's discretion\n\n          -  Secondary hypertension\n\n          -  Diabetes (type 1 and type 2 diabetes)\n\n          -  History of cancer or malignant disease within the past 5 years(excluding basal cell\n             carcinoma)\n\n          -  Any metabolic disease, gastrointestinal disorder or other clinically significant\n             disease/disorder which in the Investigator's opinion could interfere with the results\n             of the study or the safety of the subject\n\n          -  Dietary restriction (fish and other seafood allergies, citrus allergies, multiple\n             food allergies)\n\n          -  Alcohol abuse and/or illicit drug consumption; subjects consuming more than 14\n             portions of alcohol per week (one portion = 1 oz. spirits or 4 oz. wine or 11oz.\n             medium strength beer / cider) Smokers and tobacco/snuff/nicotine users\n\n          -  Consumption of natural health products targeted to blood pressure lowering within 30\n             days before randomization and during the study\n\n          -  Participation in a clinical research trial within 30 days prior to randomization or\n             during the study\n\n          -  Individuals who are cognitively impaired and/or who are unable to give informed\n             consent\n\n          -  Any other condition which in the Investigator's opinion may adversely affect the\n             subject's ability to complete the study or its measures or which may pose significant\n             risk to the subject"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974570", 
            "org_study_id": "13TBHM"
        }, 
        "intervention": [
            {
                "arm_group_label": "Marealis refined peptide concentrate", 
                "description": "2 tablets, once per day before noon", 
                "intervention_name": "Marealis refined peptide concentrate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "2 tablets, once per day before noon", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antihypertensive Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prehypertension", 
            "Hypertension", 
            "Shrimp protein hydrolysate", 
            "Marine protein hydrolysate", 
            "Ambulatory blood pressure", 
            "Blood pressure"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "630-617-2000"
                }, 
                "facility": {
                    "address": {
                        "city": "Addison", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60101"
                    }, 
                    "name": "Biofortis Inc."
                }, 
                "investigator": {
                    "last_name": "Kathleen Kelley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "604-434-2270"
                }, 
                "facility": {
                    "address": {
                        "city": "Burnaby", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5G 1T4"
                    }, 
                    "name": "Dr. Ronald Collette"
                }, 
                "investigator": {
                    "last_name": "Ronald Collette, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "519-862-1131"
                }, 
                "facility": {
                    "address": {
                        "city": "Corunna", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N0N 1G0"
                    }, 
                    "name": "Dr. William O'Mahony Medicine Professional Corporation"
                }, 
                "investigator": {
                    "last_name": "William O'Mahony, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "905-537-5558"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8J 0B6"
                    }, 
                    "name": "Dr. Steven V. Zizzo Medicine Professional Corporation"
                }, 
                "investigator": {
                    "last_name": "Steven Zizzo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "519-204-6855"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6J 0A8"
                    }, 
                    "name": "Dr. Dorli Herman"
                }, 
                "investigator": {
                    "last_name": "Dori Herman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mevans@kgksynergize.com", 
                    "last_name": "Mal Evans, PhD", 
                    "phone": "(519) 438-9374", 
                    "phone_ext": "239"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 5R8"
                    }, 
                    "name": "KGK Synergize Inc."
                }, 
                "investigator": {
                    "last_name": "Dale Wilson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "519-963-0448"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N5Y 5K7"
                    }, 
                    "name": "Schacter Medicine Professional Corporation"
                }, 
                "investigator": {
                    "last_name": "Gordon Schacter, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "519-659-4040"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N5W 6A2"
                    }, 
                    "name": "Milestone Research"
                }, 
                "investigator": {
                    "last_name": "Peter Dzongowski, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "905-898-7582"
                }, 
                "facility": {
                    "address": {
                        "city": "Newmarket", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L3Y 5G8"
                    }, 
                    "name": "SKDS Research Inc."
                }, 
                "investigator": {
                    "last_name": "Sam Henein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "519-344-6612"
                }, 
                "facility": {
                    "address": {
                        "city": "Sarnia", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N7T 4X3"
                    }, 
                    "name": "Glencar Medical Inc."
                }, 
                "investigator": {
                    "last_name": "Michael O'Mahony, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "416-741-1500"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9V 4B4"
                    }, 
                    "name": "Dr. Anil Gupta Medicine Professional Corporation"
                }, 
                "investigator": {
                    "last_name": "Anil Gupta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "(519) 537-8681"
                }, 
                "facility": {
                    "address": {
                        "city": "Woodstock", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N4S 5P5"
                    }, 
                    "name": "Devonshire Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Kenneth Heaton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension", 
        "other_outcome": [
            {
                "measure": "Mean heart rate", 
                "safety_issue": "No", 
                "time_frame": "Over 8 weeks"
            }, 
            {
                "measure": "Mean fasting serum glucose", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Mean fasting serum lipids (total cholesterol, HDL-cholesterol, LDL-cholesterol, total triglycerides)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Mean serum C-reactive protein", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Dietary variables from food records (energy, carbohydrates, fats, proteins, fiber and sodium)", 
                "safety_issue": "No", 
                "time_frame": "Over 8 weeks"
            }, 
            {
                "measure": "Mean urine sodium", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Biometrics: weight and BMI", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Blood safety parameters: complete blood count, electrolytes (Na, K, Cl), creatinine, eGFR, AST, ALT, GGT, bilirubin", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Over 8 weeks"
            }
        ], 
        "overall_contact": {
            "email": "mevans@kgksynergize.com", 
            "last_name": "Mal Evans, PhD", 
            "phone": "519-438-9374", 
            "phone_ext": "239"
        }, 
        "overall_official": {
            "affiliation": "KGK Synergize Inc.", 
            "last_name": "Dale Wilson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in daytime ambulatory systolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Change in office systolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974570"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in 24-hour and nighttime ambulatory systolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Change in 24-hour, daytime and nighttime ambulatory diastolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Changes in 24-hour, daytime and nighttime ambulatory systolic and ambulatory diastolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Mean ambulatory systolic blood pressure (24-hour, daytime and nighttime)", 
                "safety_issue": "No", 
                "time_frame": "Over 8 weeks"
            }, 
            {
                "measure": "Mean ambulatory diastolic blood pressure (24-hour, daytime and nighttime)", 
                "safety_issue": "No", 
                "time_frame": "Over 8 weeks"
            }, 
            {
                "measure": "Change in office diastolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Changes in office systolic and office diastolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Changes in office systolic and office diastolic blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Mean Office systolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Over 8 weeks"
            }, 
            {
                "measure": "Mean Office diastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Over 8 weeks"
            }
        ], 
        "source": "KGK Synergize Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Marealis AS", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "KGK Synergize Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}